HCA Healthcare, Inc.

LSE:0J1R Stock Report

Market Cap: US$76.0b

HCA Healthcare Valuation

Is 0J1R undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0J1R when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0J1R ($301.1) is trading below our estimate of fair value ($556.15)

Significantly Below Fair Value: 0J1R is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0J1R?

Key metric: As 0J1R is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0J1R. This is calculated by dividing 0J1R's market cap by their current earnings.
What is 0J1R's PE Ratio?
PE Ratio12.7x
EarningsUS$5.93b
Market CapUS$76.03b

Price to Earnings Ratio vs Peers

How does 0J1R's PE Ratio compare to its peers?

The above table shows the PE ratio for 0J1R vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average28x
MDC Mediclinic International
21.9x10.7%UK£3.7b
SPI Spire Healthcare Group
32.4x26.9%UK£917.6m
CVSG CVS Group
22.5x15.5%UK£590.4m
SN. Smith & Nephew
35.1x22.7%UK£8.7b
0J1R HCA Healthcare
12.7x6.0%US$76.0b

Price-To-Earnings vs Peers: 0J1R is good value based on its Price-To-Earnings Ratio (12.7x) compared to the peer average (30x).

Price to Earnings Ratio vs Industry

How does 0J1R's PE Ratio compare vs other companies in the European Healthcare Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0J1R 12.7xIndustry Avg. 18.9xNo. of Companies6PE01020304050+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0J1R is good value based on its Price-To-Earnings Ratio (12.7x) compared to the European Healthcare industry average (18.4x).

Price to Earnings Ratio vs Fair Ratio

What is 0J1R's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0J1R PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.7x
Fair PE Ratio38.8x

Price-To-Earnings vs Fair Ratio: 0J1R is good value based on its Price-To-Earnings Ratio (12.7x) compared to the estimated Fair Price-To-Earnings Ratio (38.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0J1R forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$298.18
US$398.84
+33.8%
10.0%US$460.00US$316.00n/a23
Dec ’25US$327.22
US$404.19
+23.5%
8.8%US$460.00US$316.00n/a23
Nov ’25US$358.07
US$407.10
+13.7%
7.7%US$460.00US$316.00n/a24
Oct ’25US$403.12
US$396.60
-1.6%
7.5%US$455.00US$316.00n/a24
Sep ’25US$391.64
US$389.58
-0.5%
6.5%US$438.00US$316.00n/a23
Aug ’25US$361.97
US$380.27
+5.1%
5.8%US$410.00US$316.00n/a23
Jul ’25US$314.76
US$353.07
+12.2%
7.7%US$397.00US$285.00n/a23
Jun ’25US$332.95
US$348.68
+4.7%
7.0%US$396.00US$285.00n/a23
May ’25US$310.06
US$343.58
+10.8%
6.8%US$378.00US$285.00n/a23
Apr ’25US$332.90
US$337.54
+1.4%
6.1%US$378.00US$285.00n/a23
Mar ’25US$312.86
US$330.47
+5.6%
7.9%US$371.00US$250.00n/a22
Feb ’25US$311.99
US$317.21
+1.7%
10.0%US$360.00US$250.00n/a20
Jan ’25US$271.10
US$287.87
+6.2%
8.2%US$338.00US$250.00US$299.1821
Dec ’24US$252.27
US$281.53
+11.6%
6.2%US$315.00US$250.00US$327.2221
Nov ’24US$224.18
US$284.77
+27.0%
6.0%US$315.00US$254.00US$358.0721
Oct ’24US$245.48
US$317.24
+29.2%
6.9%US$350.00US$260.00US$403.1221
Sep ’24US$279.75
US$317.95
+13.7%
6.7%US$350.00US$260.00US$391.6422
Aug ’24US$273.21
US$317.14
+16.1%
6.9%US$350.00US$260.00US$361.9722
Jul ’24US$303.51
US$314.64
+3.7%
6.9%US$350.00US$260.00US$314.7622
Jun ’24US$268.36
US$310.95
+15.9%
6.8%US$350.00US$260.00US$332.9522
May ’24US$284.73
US$307.00
+7.8%
7.6%US$350.00US$260.00US$310.0622
Apr ’24US$261.10
US$280.91
+7.6%
6.5%US$310.00US$239.00US$332.9022
Mar ’24US$244.28
US$280.91
+15.0%
6.5%US$310.00US$239.00US$312.8622
Feb ’24US$257.30
US$277.00
+7.7%
7.0%US$310.00US$235.00US$311.9922
Jan ’24US$238.25
US$248.10
+4.1%
8.4%US$286.00US$217.00US$271.1021

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 06:43
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HCA Healthcare, Inc. is covered by 49 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Hua HaBaird
Ishan MajumdarBaptista Research